Seroatlas · Human Serome Atlas

TICAM2

TIR domain-containing adapter molecule 2

Also known as: TCAM2_HUMAN, TICAM-2, TIRP, TRAM

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86XR7
Gene: TICAM2
Ensembl: ENSG00000243414
Chromosome: 5
Canonical length: 235 aa
Protein class: Predicted intracellular proteins, Transporters
Quaternary structure: Homodimer

OverviewNCBI Gene

Enables molecular adaptor activity. Involved in several processes, including positive regulation of interleukin-18-mediated signaling pathway; regulation of cytokine production; and regulation of innate immune response. Located in endoplasmic reticulum; endosome; and phagocytic cup. Is active in endosome membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

235 residues, UniProt reviewed canonical sequence.

>Q86XR7|TICAM2
     1  MGIGKSKINS CPLSLSWGKR HSVDTSPGYH ESDSKKSEDL SLCNVAEHSN TTEGPTGKQE
    61  GAQSVEEMFE EEAEEEVFLK FVILHAEDDT DEALRVQNLL QDDFGIKPGI IFAEMPCGRQ
   121  HLQNLDDAVN GSAWTILLLT ENFLRDTWCN FQFYTSLMNS VNRQHKYNSV IPMRPLNNPL
   181  PRERTPFALQ TINALEEESR GFPTQVERIF QESVYKTQQT IWKETRNMVQ RQFIA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TICAM2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.43
Highest tissue expression: 6.5 nTPM

Expression across tissuesHPA

Tissue

skeletal muscle: 6.5 nTPM
spleen: 3.6 nTPM
lymph node: 3.4 nTPM
appendix: 3.2 nTPM
cervix: 3 nTPM
epididymis: 3 nTPM

Single-cell type

microglia: 31 nCPM
choroid plexus epithelial cells: 14 nCPM
oligodendrocytes: 13 nCPM
oligodendrocyte progenitor cells: 12 nCPM
astrocytes: 12 nCPM
bergmann glia: 11 nCPM

Immune cell

intermediate monocyte: 8.3 nTPM
classical monocyte: 7.4 nTPM
non-classical monocyte: 6.4 nTPM
myeloid DC: 6.3 nTPM
plasmacytoid DC: 3.7 nTPM
memory B-cell: 2.7 nTPM

Brain region

thalamus: 5 nTPM
spinal cord: 4.5 nTPM
medulla oblongata: 4.4 nTPM
white matter: 4.4 nTPM
cerebral cortex: 4.3 nTPM
midbrain: 4.1 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.8
gnomAD pLI: 0
gnomAD missense Z: 0.83
DepMap mean gene effect: -0.05
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of TICAM2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TICAM2 as an antibody target. Whether an autoantibody or antibody against TICAM2 could matter depends on whether native TICAM2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TICAM2 is annotated at the cell surface, where native TICAM2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label TICAM2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...